Three independent discounted-cash-flow-style models value BridgeBio Pharma, Inc. Common Stock every trading day. 0 of 3 currently price BBIO above its market price.
| Free Cash Flow model | $-4,211.85 |
| Excess Profit model | $-5,043.57 |
| Residual Earnings model | $-3.24 |
| Dividend Discount model | — |
| Piotroski F-Score | 3 / 9 |
| Return on invested capital | +10.0% |
| Net debt / EBITDA | — |
| Gross margin | +95.8% |
| Revenue CAGR | +86.3% |
| Cash conversion | — |
| Dividend yield | — |
| Buyback yield | -2.9% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open BBIO in StockKitty